Exai Bio Novel RNA-based Liquid Biopsy Platform May Detect Colorectal Cancer Early

Exai Bio, a next-generation liquid biopsy company, and researchers led by Professor Hani Goodarzi at UCSF are presenting data from a new study in a poster entitled "Serum-based colorectal cancer detection using orphan noncoding RNAs" at the 2022 European Society of Medical Oncology (ESMO) meeting. This case-control study of 191 subjects demonstrated that Exai’s novel, RNA-based platform accurately predicted colorectal cancer (CRC) cases versus non-cancer controls, both overall and across the full ranges of cancer stages and categories of tumor size/extent.